# Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer

Source: [Medical Xpress - latest medical and health news stories](https://medicalxpress.com/news/2026-11-experimental-gls-inhibitor-antitumor-advanced.html) · 2026-11-19 · Medicine
Page: https://themorning.science/story/experimental-gls-1-inhibitor-demonstrates-antitumor-activity-in-advanced-treatme-6bce8d4eb1a83482
Kind: research · Impact: medium

## In brief

- A Phase I trial tested the experimental GLS-1 inhibitor IACS-6274 combined with bevacizumab and paclitaxel chemotherapy in patients with advanced platinum-resistant ovarian cancer.
- Researchers presenting the new results reported promising antitumor activity for the combination.

## Why it matters

Early-phase signals of activity for a GLS-1 inhibitor combination in treatment-resistant ovarian cancer are relevant to researchers following metabolic approaches to cancer therapy.

## Coverage

- [Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer](https://medicalxpress.com/news/2026-11-experimental-gls-inhibitor-antitumor-advanced.html) — Medical Xpress - latest medical and health news stories, 2026-11-19

Tags: ovarian cancer, glutaminase inhibitor, clinical trial, cancer therapy, drug combination

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
